KBC Group
OSIR

KBC Group’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

KBC Group’s Portfolio OSIR Stock Details OSIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-6,796
Closed -$33K – 1368
2016
Q4 		$33K Sell
6,796
-2,753
-29% -$14.1K ﹤0.01% 1285
2016
Q3 		$47K Sell
9,549
-3,145
-25% -$16.1K ﹤0.01% 1259
2016
Q2 		$65K Buy
+12,694
New +$68.4K ﹤0.01% 1201

Other funds holding OSIR

HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return
Public Employees Retirement Association of Colorado
Public Employees Retirement Association of Colorado Denver, Colorado $25.5B AUM 28.85% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

KBC Group's OSIR Position: Q1 2017 in Review

KBC Group sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q1 2017, closing a stake of 6,796 shares — an estimated $33K sold.

KBC Group first reported a position in OSIR in Q2 2016 and held it in 3 quarters. The position peaked at $65K in Q2 2016. 11 funds tracked by Wall St. Rank hold OSIR as of Q1 2017.

  • KBC Group reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • KBC Group sold 6,796 Osiris Therapeutics, Inc. Common Stock shares in Q1 2017, an estimated $33K.
  • KBC Group first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2016 and held it in 3 quarters.
  • KBC Group's Osiris Therapeutics, Inc. Common Stock position peaked at $65K in Q2 2016.
  • 11 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q1 2017.

Based on KBC Group's 13F filing for Q1 2017, filed 10 May 2017.